If you are wondering whether Abbott Laboratories at around US$91.07 is a bargain or a value trap, you will want to look closely at what the current valuation is really telling you. The stock has risen 3.7% over the past week and 8.0% over the past month, yet it remains down 26.7% year to date and down 30.3% over the last year, which raises fair questions about how sentiment and risk perception have shifted. Recent headlines have focused on Abbott Laboratories as a large healthcare player,...

Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes. Findings from multiple Abbott studies shared at the American Diabetes Association's (ADA) June 2026 86th Scientific Sessions show sharp increases in DKA-related hospitalizations across all age groups nationwide. The data reinforces that while diabetes technology has advanced sig